Medpace Hldgs Option Alert: Dec 19 $540 Calls at the Bid: 80 vs 6 OI

Medpace Hldgs Option Alert: Dec 19 $540 Calls at the Bid: 80 @ $63.0 vs 6 OI; Ref=$590.0

Medpace Hldgs

MEDPACE HOLDINGS INC

Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.

Pharmacy,,Pills,And,Box,With,Healthcare,Store,,Shelf,And,Prescription

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

MEDP

RXRX

Hanno registrato rally impressionanti, ma ora un indicatore tecnico suona un campanello d&#39;allarme. Ecco di chi si tratta.

È ora di vendere? 2 titoli del settore sanitario che potrebbero esplodere

Usa,,California,-,01,October,2019:,Coca,Cola,Bottle,With

FARM

Giornata di trimestrali per i big di Wall Street. Ma sono due azioni inattese a scatenare gli acquisti con performance eccezionali.

I 5 titoli da monitorare oggi: da Coca-Cola a due sorprese nel pre-market

Medpace Holdings Inc

MedPeer Inc

Legal

Press Releases

MEDP Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Medpace Holdings, Inc. (NASDAQ: MEDP) Investors with Significant Losses to Contact the Firm

Medpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 10, 2025

Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Results

Medpace Holdings, Inc. to Report First Quarter 2025 Financial Results on April 21, 2025

Medpace Holdings, Inc. Reports First Quarter 2025 Results

Medpace Holdings, Inc. to Report Second Quarter 2025 Financial Results on July 21, 2025

Medpace Holdings, Inc. Reports Second Quarter 2025 Results

Medpace Holdings, Inc. to Report Third Quarter 2025 Financial Results on October 22, 2025

Medpace Holdings, Inc. Reports Third Quarter 2025 Results

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Evotec

Icon

Illumina

IQVIA Hldgs

Mettler-Toledo International, Inc. Common Stock

Mettler-Toledo Intl

Qiagen

Repligen

Revvity

Sotera Health

Stevanato Group

Bio-Techne

Tempus AI

Thermo Fisher Scientific Inc Common Stock

Thermo Fisher Scientific

10x Genomics

Waters

West Pharmaceutical Services, Inc. Common Stock

West Pharmaceutical Servs

Mizuho

Barclays

Jefferies

Rothschild & Co

WIIM

Medpace Holdings shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 guidance above estimates.

Comments

Medpace Hldgs

Unusual Options Activity for

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO